Stocks · Health care · Pharmaceutical Preparations

Sagimet Biosciences Inc.

SGMT Clue Score32
United States Fiscal year ends December CIK 0001400118 Results filed 11 Aug 2026

What the insiders did Net selling

By person

14 insiders · 24 transactions
12.0×

David Happel holds 12.0 times base salary in stock. $7.59M of shares against $630.00K in salary for 2025.

Salary from the company's own proxy. The shares are what David Happel last reported holding, valued at $10.23, the price Series A Common Stock was last bought or sold at on the open market here, on 14 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
George Kemble
Director
—
$4.34M (6) scheduled
−$4.34M
62,161
$636.08K
—
David Happel
President & CEO
$71.68K (3)
$1.16M (3)
−$1.09M
741,570
$7.59M
—
Beth C Seidenberg
Director
$750.00K (1)
—
+$750.00K
131,643
$1.35M
—
New Enterprise Associates 13 LP entity
10% owner
$480.00K (1)
$10.59K (1) scheduled
+$469.41K
3,000,275
$30.70M
+7,863%
Elizabeth Rozek
Chief Legal & Admin. Officer
—
$228.19K (4)
−$228.19K
224,414
$2.30M
—
Eduardo Bruno Martins
Chief Medical Officer
—
$121.03K (3)
−$121.03K
147,296
$1.51M
—
Thierry Chauche
Chief Financial Officer
—
$7.03K (1)
−$7.03K
59,688
$610.78K
—
NEA Partners 13, Limited Partnership entity
10% owner
—
—
—
3,000,275
$30.70M
−22.1%
KPCB PBD Associates, LLC entity
10% owner
—
—
—
1,899,475
$19.44M
+4,800%
Jinzi Jason Wu
Director
—
—
—
1,654,701
$16.93M
—
Patrick J Kerins
10% owner
—
—
—
13,139
$134.45K
−98.5%
Merdad Parsey
Director
—
—
—
12,794
$130.92K
+47.4%
Forest Baskett
10% owner
—
—
—
11,300
$115.63K
−98.7%
Scott D Sandell
10% owner
—
—
—
6,997
$71.60K
−99.2%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.